Bifunctional degraders of galactose-deficient immunoglobulins
US-2025228957-A1 · Jul 17, 2025 · US
This page is not indexed by search engines while we improve data quality.
Dubowchik Gene M patents
Dubowchik Gene M is listed as an inventor on 26 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Dubowchik Gene M |
| Total patents | 26 |
| First publication | Sep 22, 2016 |
| Latest publication | Jul 17, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Antibody drug conjugates using mates technology for delivering cytotoxic agents
US-2025108124-A1 · Apr 3, 2025 · US
Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides
US-12097241-B2 · Sep 24, 2024 · US
Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides
US-12097242-B2 · Sep 24, 2024 · US
Bifunctional degraders of galactose-deficient immunoglobulins
US-2024309114-A1 · Sep 19, 2024 · US
Agents for directed conjugation techniques and conjugated products
US-2024252674-A1 · Aug 1, 2024 · US
Prodrugs of myeloperoxidase inhibitors
US-2024067651-A1 · Feb 29, 2024 · US
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US-2022331402-A1 · Oct 20, 2022 · US
Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
US-2022249468-A1 · Aug 11, 2022 · US
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US-2022211812-A1 · Jul 7, 2022 · US
Recent patents
Latest publications not already listed above.
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
US-11364281-B2 · Jun 21, 2022 · US
Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
US-11185570-B2 · Nov 30, 2021 · US
Pyrimidine carboxamides as GSK-3 inhibitors
US-11053258-B2 · Jul 6, 2021 · US
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US-2021196791-A1 · Jul 1, 2021 · US
GSK-3 inhibitors
US-10774086-B2 · Sep 15, 2020 · US
GSK-3 inhibitors
US-10752609-B2 · Aug 25, 2020 · US
Pyrimidine carboxamides as gsk-3 inhibitors
US-2020181170-A1 · Jun 11, 2020 · US
Gsk-3 inhibitors
US-2019315714-A1 · Oct 17, 2019 · US
Gsk-3 inhibitors
US-2019276463-A1 · Sep 12, 2019 · US
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US-2019256570-A1 · Aug 22, 2019 · US
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US-10266578-B2 · Apr 23, 2019 · US
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US-2018222960-A1 · Aug 9, 2018 · US
Substituted pyridine derivatives useful as GSK-3 inhibitors
US-9809573-B2 · Nov 7, 2017 · US
GSK-3 inhibitors
US-9718804-B2 · Aug 1, 2017 · US
Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors
US-2016289210-A1 · Oct 6, 2016 · US
Gsk-3 inhibitors
US-2016272621-A1 · Sep 22, 2016 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Bristol Myers Squibb Co | 20 |
| Biohaven Therapeutics Ltd | 5 |
| Scherer Technologies Llc R P | 1 |
| Biohaven Pharm Holding Co Ltd | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.